Key Takeaways
- Revenue crosses $100M run rate, but margin resets: Q3 revenue growth was driven by Digital and Financial Markets, yet EBITDA margin fell as one-off Q2 benefits reversed, utilization normalized, and new facility costs began to bite.
- Growth is coming from outside the top 10: Non-top-10 clients drove the quarter's expansion, while management saw no directional weakness in any particular large account.
- GenAI is enhancing the pipeline, not yet the P&L: No direct GenAI deal wins or monetization uplift have materialized, but the technology-plus-domain combination is lifting ACV and win rates.
- Investment mode continues, capping margin upside: Management will keep spending on new centers, sales hires, and capabilities as long as growth persists, explicitly declining to call an end to the investment phase.
- What to watch next quarter: Whether lower Q3 roll-offs actually convert into better Q4 growth, the pace of new facility cost absorption, and any signal on FY26 EBITDA band narrowing at full-year results.
Revenue Drivers & Client Dynamics
- Digital and Financial Markets lead: Q3 growth was powered by the Digital segment (Analytics, MarTech, Creative Services on a low Q2 base) and Financial Markets (predominantly Trade LifeCycle). The A&A business picked up on change and transformation work.
- Non-top-10 clients fuel expansion: Growth this quarter came from clients outside the top 10. Management stated there is no directional view to read into this and no weakness in any particular top account.
- Roll-off headwind easing: Roll-offs were higher in Q2 and came down in Q3. All else equal, this should produce better Q4 performance than Q3.
- Cable and wireless pressure is structural: Telecom clients face declining technology costs and subscribers demanding higher bandwidth at lower prices. Clients are trying to reinvent as tech solutions providers while price competitiveness drives subscriber shifts. Retention efforts are underway.
- Cross-sell green shoots, still early: Management is seeing initial signs of cross-sell opportunities as digital services begin to resonate outside traditional digital industries, but it remains early days.
- Client budgets for 2025: Feedback is neutral to positive. Clients delivered excellent results but are worried about policies. With only ~10 days since the new US administration, it is too early to exhibit any view on client behavior change.
Kapil Jain: "I wouldn't say just GenAI alone, I'm saying technology, GenAI, domain - a combination of all this together is a unique value proposition which has helped us to enhance our pipeline and the ACV of the deals."
Margin Walk & Cost Structure
- Q3 margin decline unpacked: EBITDA margin fell because one-off benefits present in Q2 reversed, utilization dropped to its medium-to-long-term average, and legal fees rose for the new Peru entity setup and tax consulting.
- New facilities add cost before revenue: 1,800 seats across Mohali, Pune, and Mumbai went live late in Q3, bringing housekeeping, security, and transportation costs. The full impact lands in Q4.
- Q4 margin headwinds quantified: G&A cost will be roughly flat to 10–20 bps higher than Q3, as new facility costs offset the reduction in temporary facility rent. Below EBITDA, expect a ~50 bps impact from the new facilities. Normalization is at least one quarter away, possibly two.
- Utilization is deliberate, not accidental: The company invests and brings people ahead of demand to avoid cannibalizing top-line growth. Q3 utilization was in line with the long-term average, not a signal of weakening demand.
- S&M expenses stable: Sales and marketing spend is expected to remain in the current 12%–13% range and is not expected to rise.
Kapil Jain: "I think at this point in time, I would say that we will continue to stay in the range that we had given you 24% to 28%. And predicting beyond that, given the overall size of the book, which is about $100 million a small movement can have a big impact on the EBITDA."
GenAI, Technology & the Pipeline
- GenAI: pipeline lever, not revenue line: Management is not seeing direct deals or monetization from GenAI investments yet. However, the technology-plus-domain combination is a value lever that is enhancing the pipeline and helping win additional business with higher ACV.
- Pilots underway, no uplift quantified: GenAI pilots are in progress but have produced no significant monetization uplift. The client discussion has shifted from FTE reduction toward effectiveness and outcome-based value.
- Agentic AI platform in early build: eClerx has built "Roboworx CogniFlows" on its enhanced Roboworx platform. It is not yet at a stage where productivity savings for clients can be quantified. Use cases are being worked on internally for shared services and the digital side.
- BPAAS reporting to be rethought: Management is revisiting how to report BPAAS for FY26 onwards because all services now use underlying technology. 100% of the business has digital/BPaaS-like characteristics, but the company was conservative in its reporting.
- Pricing remains value-based, not cost-based: There is no downward pressure on pricing. Management describes pricing as efficient and value-based, not cost-based.
- Deal tenure and ticket size stable: No directional shift in deal tenure is visible. There is a marginal increase in per-deal ticket size, but it is not substantial.
Kapil Jain: "What I said was that we are not seeing deals in that area or monetization of the investments and efforts that's going in. In terms of direct that look, you have won X million dollars in GenAI business. Are we seeing the value lever in the pipeline or winning additional businesses because of the underlying technology? The answer is yes."
Delivery Footprint & Operating Model
- Peru subsidiary set up, launch imminent: A new subsidiary in Peru has been established and will launch operations in late Q4.
- Manila delivery center adding Care: The Manila center is expected to begin providing Care support.
- Onshore delivery carries a premium: Onshore staff have consulting skills and higher billing rates, approximately 3.5x–4x offshore rates. Subcontracting is higher onshore due to difficulty finding quality resources, used judiciously for urgent client needs.
- GCC relationship is collaborative, not competitive: eClerx works with all clients' GCCs and sees co-existence as valued. There is very little direct business with GCCs; the preference is to contract directly with the US or UK-based client entity.
- Sales hiring shifts toward generalists: The company is hiring more generalist salespeople who can take services across client segments, leveraging existing domain and practice capability.
- H1B reliance is zero: Management stated the company has no reliance on H1B visas and is able to hire local talent.
Investment Philosophy & Capital Allocation
- Investment continues as long as growth does: Management explicitly frames eClerx as a growth business. It will continue investing in new geographies, capabilities, and offerings as long as growth is visible, and will stop only when growth momentum comes down.
- No end to investment phase called: When asked if the investment phase is done and operating EBITDA should start increasing, management declined to agree, stating the business is not mature and will keep investing.
- Bottom line to outpace top line over time: Over a 2–3 year horizon, management expects the bottom line to have a better gradient than the top line.
- DSO improvement a focus: The company will try to bring DSO down consistently. Some invoicing processes remain manual, and governance is being strengthened.
- New center exploration underway: Management is exploring opening another center.
Kapil Jain: "We are a growth business until such time we see growth, we will continue to invest in the business. And we will stop investing when we see growth momentum coming down and I hope that doesn't happen."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 growth improvement | Roll-offs came down in Q3; all else equal, Q4 performance should be better than Q3 | Q4 FY25 |
| Q4 margin headwind | ~50 bps impact below EBITDA from new facilities; G&A flat to +10–20 bps QoQ | Q4 FY25 |
| Facility cost normalization | New facility cost absorption normalizing | At least 1 quarter away, possibly 2 |
| EBITDA margin band | Will continue to operate within 24%–28% | Ongoing |
| Bottom-line vs top-line gradient | Bottom line to have better gradient than top line | Over 2–3 years |
| S&M expense range | Expected to remain in 12%–13% range | Ongoing |
| Operating EBITDA guidance | Will revisit giving a full-year operating EBITDA band | Next earnings call (full-year results) |
| EBITDA band narrowing | Will consider request to narrow the 24%–28% range | When coming for full-year results |
| BPAAS reporting definition | Will revisit definition | FY26 onwards |
| Peru operations launch | New subsidiary to begin operations | Late Q4 FY25 |
| Manila Care support | Expect to start providing Care support from Manila | Not specified |
| Investment continuation | Will continue investing as long as growth is seen; will stop when growth momentum comes down | Conditional on growth |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Operating revenue (USD) | $100.7 million, up 1.8% QoQ, 2.2% in constant currency, 11.2% YoY |
| Operating revenue (INR) | ₹853.8 crore, up 2.6% QoQ, 14% for the nine-month period |
| Total revenue | ₹875.2 crore, up 3.6% QoQ, 13% YoY |
| Other income | ₹21.4 crore, largely from revaluation income on INR depreciation |
| EBITDA | ₹228.1 crore, margin 26.1%, flat sequentially and YoY |
| PAT | ₹137.1 crore, margin 15.7% |
| EBITDA margin guidance (FY25) | 24% to 28% |
| Analytics and Automation revenue | $20.8 million, up 9% QoQ |
| ACV of deal wins | $33 million, up sequentially |
| Exit headcount | 18,642, up approximately 400 QoQ |
| Attrition | 19% |
| Top 10 client concentration | ~62% |
| DSO | 83 days, compared to 77 in the previous quarter |
| Seating capacity increase | 1,800 seats, new facilities in Mohali, Pune and Mumbai went live |
| Roll-off rate | 15% to 20% of top line |
| Sales and distribution expenses | 12% to 13% of revenue, same as last year |